Clinical Trials Search

Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Thakar MD, Keyur
Sponsor: NCI
Details (Identifier #): NCT02502266
Title: Protocol NRG-GY005,A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Department: Oncology
Diagnosis: Hematology- Multiple Myeloma
Principal Investigator: Lash MD, Bradley
Sponsor: BMS
Details (Identifier #): NCT02726581
Title: BMS CA209-602, A Phase 2/3 Trial Combining Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: NSABP Foundation
Details (Identifier #): NCT02664077
Title: NSABP C-13, A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)
Department: Oncology
Diagnosis: Head and Neck
Principal Investigator: Lash MD, Bradley
Sponsor: BMS
Details (Identifier #): NCT02823574
Title: BMS CA209-714,A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in combination with Ipilimumab placebo Squamous Cell Carcinoma of the Head and Neck (SCCHN) (CheckMate 714: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 714)
Department: Oncology
Diagnosis: Gastrointestinal - Pancreas
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Details (Identifier #): NCT01013649
Title: RTOG0848, A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma